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1. INTRODUCTION {#cam41666-sec-0005}
===============

Approximately 90% of adult glioblastomas (GBMs) present as de novo GBMs (primary GBMs) without antecedent history of a less‐malignant precursor lesion, and the remaining cases progress from WHO lower grade (WHO II‐III) diffuse gliomas (secondary GBMs).[1](#cam41666-bib-0001){ref-type="ref"}, [2](#cam41666-bib-0002){ref-type="ref"} Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutations are recognized as definitive diagnostic molecular biomarkers of secondary GBM and are more prognostically valuable than the history of tumor onset.[3](#cam41666-bib-0003){ref-type="ref"} Correspondingly, wild‐type IDH1/2 genotypes are considered robust biomarkers of primary GBM (\<5%).[4](#cam41666-bib-0004){ref-type="ref"}, [5](#cam41666-bib-0005){ref-type="ref"} Epigenetic alterations affecting the MGMT promoter methylation status and genetic mutations in the TERT promoter are considered molecular signatures of GBM,[6](#cam41666-bib-0006){ref-type="ref"} but few studies have investigated the prognostic significance of these molecular features in adult primary GBM. The diagnosis and monitoring of GBMs in neurosurgical practice are often accomplished through MRI visualization. MRI‐derived features can be used to assess the entire tumor without sampling error, but few studies have attempted to integrate molecular alterations, MRI‐derived features, and clinical features into a single survival analysis model. Such a model would more robustly predict the outcomes of adult primary GBM patients than models that consider each factor independently.

2. MATERIALS AND METHODS {#cam41666-sec-0006}
========================

2.1. Patients and tumor samples {#cam41666-sec-0007}
-------------------------------

This retrospective study was approved by the Ethics Committee and Institutional Review Board of Tianjin Huanhu Hospital. In accordance with the Declaration of Helsinki, written informed consent for the use of clinical information and tissues was obtained from the patients.

A total of 560 adult GBM patients were analyzed in this retrospective study. These patients were preoperatively diagnosed as having a high‐grade glioma by neuroimaging (CT or MRI), and the glioma was confirmed as GBM by postoperative histopathology. Both the operations and the histopathological assessments were performed from January 2011 to January 2013. A diagram depicting the patient selection process is shown in Figure [1](#cam41666-fig-0001){ref-type="fig"}. We selected the included patients based on the stringent criteria defined by the CGCG clinical treatment guidelines.[7](#cam41666-bib-0007){ref-type="ref"} Briefly, the selected patients were treated with radiotherapy plus concomitant and adjuvant TMZ chemotherapy after maximal safe resection of the tumor. TMZ was administered at a daily dose of 75 mg/m^2^ (7 days a week) during radiotherapy.

![Flowchart of Patient Selection](CAM4-7-3704-g001){#cam41666-fig-0001}

2.2. DNA extraction and molecular analysis {#cam41666-sec-0008}
------------------------------------------

The presence of hotspot mutations in IDH (IDH1‐R132, IDH2‐R140, IDH2‐R172) and TERT (C228T/C250T) in all the cases included in this study was detected by Sanger sequencing, as previously described.[8](#cam41666-bib-0008){ref-type="ref"}, [9](#cam41666-bib-0009){ref-type="ref"} The methylation status of the MGMT promoter was analyzed by pyrosequencing, as previously described.[10](#cam41666-bib-0010){ref-type="ref"}

2.3. Analysis of MRI‐derived features {#cam41666-sec-0009}
-------------------------------------

MRI sequences were acquired on a 1.5T scanner (GEMS 1234) and included SE T1WI (TR/TE: 2126/22), FRFSE T2WI (TR/TE: 4300/102), T2FLAIR (TR/TE: 8502/125) and diffusion‐weighted imaging sequences (TR/TE: 6000/76, *b* value: 0 s/mm^2^ and 1000 s/mm^2^). The parameters used for imaging were a section thickness of 6 mm, an intersection gap of 1 mm, a PFOV of 24 cm × 24 cm, and a 320 × 224 matrix. Contrast‐enhanced T1‐weighted images were acquired immediately following injection of the contrast agent Gd‐DTPA. Diffusion‐weighted imaging was performed prior to contrast‐enhanced T1‐weighted imaging. The ADC value was calculated as previously described.[11](#cam41666-bib-0011){ref-type="ref"} The MRI scans were interpreted by two neuroradiologists blinded to the patient outcome. We selected eight cardinal tumor‐related imaging features and dichotomized these features according to previous guidelines using the following criteria: ADC value,[12](#cam41666-bib-0012){ref-type="ref"}, [13](#cam41666-bib-0013){ref-type="ref"} peritumoral edema,[14](#cam41666-bib-0014){ref-type="ref"} contrast‐enhancing tumor (CET),[15](#cam41666-bib-0015){ref-type="ref"} necrosis,[16](#cam41666-bib-0016){ref-type="ref"} formation of cysts (cyst),[16](#cam41666-bib-0016){ref-type="ref"} noncontrast‐enhancing tumor (nCET),[17](#cam41666-bib-0017){ref-type="ref"} T1/Flair ratio,[16](#cam41666-bib-0016){ref-type="ref"} and deep white matter invasion.[15](#cam41666-bib-0015){ref-type="ref"} The exact dichotomy information is listed in Table [1](#cam41666-tbl-0001){ref-type="table"}.

###### 

The relations between molecular biomarkers and adult primary GBM‐related features

  Variables                    MGMT promoter   TERT promoter   Ki‐67 LI                                                                       
  ---------------------------- --------------- --------------- ---------- -------- ---- ----- ----------- ------------ ---- ---- ------------ -------------
  ADC                                                                                                                                         
  \>ADC_mean                   52              80              0.091      0.7633   47   85    0.482       0.4877       72   60   **6.3498**   **0.01174**
  ≤ADC_mean                    50              83              42         91       52   81                                                    
  Edema                                                                                                                                       
  Mild to moderate             47              56              3.629      0.0568   38   65    0.827       0.3632       44   59   1.1232       0.2891
  Severe                       55              107             51         111      80   82                                                    
  T1/Flair                                                                                                                                    
  T1\~Flair                    44              62              0.680      0.4096   27   79    **5.214**   **0.0224**   56   50   2.587        0.1078
  T1 \< Flair                  58              101             62         97       68   91                                                    
  CET                                                                                                                                         
  Unobvious (\<33%)            50              97              2.793      0.0946   44   103   1.975       0.1599       68   79   0.038        0.8458
  Obvious (≥33%)               52              66                                  45   73                             56   62                
  Deep white matter invasion                                                                                                                  
  Absent                       35              64              0.657      0.4176   34   65    0.041       0.84         47   52   0.0296       0.8635
  Present                      67              99              55         111      77   89                                                    
  Necrosis                                                                                                                                    
  Unobvious (\<33%)            47              61              1.947      0.163    46   62    **6.631**   **0.0100**   46   62   1.292        0.2558
  Obvious (≥33%)               55              102             43         114      78   79                                                    
  Cysts                                                                                                                                       
  Present                      43              53              2.525      0.1121   34   62    0.226       0.6342       36   60   **5.221**    **0.0223**
  Absent                       59              110             55         114      88   81                                                    
  KPS                                                                                                                                         
  ≥80                          58              80              1.523      0.2172   45   93    0.123       0.7258       59   79   1.887        0.1696
  \<80                         44              83              44         83       65   62                                                    
  Age                                                                                                                                         
  \<50                         52              99              2.436      0.1186   57   94    2.728       0.099        74   77   0.6912       0.4058
  ≥50                          50              64              32         82       50   64                                                    
  Gender                                                                                                                                      
  Female                       49              81              0.069      0.7933   42   88    0.187       0.6657       54   76   2.8293       0.0926
  Male                         53              82              47         88       70   65                                                    
  nCET                                                                                                                                        
  Obvious (≥33%)               44              55              2.366      0.124    30   69    0.763       0.3823       52   47   2.086        0.1486
  Unobvious (\<33%)            58              108             59         107      72   94                                                    
  MGMT promoter                                                                                                                               
  Methylated                                                                       32   70    0.364       0.5464       40   62   3.8236       0.051
  Unmethylated                                                                     57   106   84          79                                  
  TERT promoter                                                                                                                               
  WT                           32              57              0.364      0.5464                                       45   44   0.765        0.3819
  Mut                          70              106                                            79          97                                  
  Ki‐67                                                                                                                                       
  High                         40              84              3.824      0.051    45   79    0.765       0.3819                              
  Low                          62              79              44         97                                                                  
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2.4. Immunohistochemical (IHC) analysis for Ki‐67 {#cam41666-sec-0010}
-------------------------------------------------

An IHC analysis was performed to obtain the labeling index (LI) for Ki‐67, and IHC staining of Ki‐67 was performed using a primary anti‐Ki‐67 antibody (1:100 dilution; catalogue no. ab8191; Abcam, Shanghai, China). The IHC protocols were previously described in detail.[18](#cam41666-bib-0018){ref-type="ref"} We dichotomized the Ki‐67 LIs by the mean values obtained for tumor cases.[18](#cam41666-bib-0018){ref-type="ref"}

2.5. Statistical analysis {#cam41666-sec-0011}
-------------------------

Clinical demographic and MRI‐derived features were compared in combination with the MGMT promoter methylation status, the TERT promoter mutation status and the Ki‐67 LI using the Pearson chi‐squared test (R version 3.3.2). Random survival forest analysis was performed using the "randomForestSRC" and "ggRandomForests" R packages (ntree = 10 000 and nsplit = 10). LASSO analysis was completed using the "glmnet" R package. The optimal shrinkage parameter (lambda) was selected by cross‐validation. Survival curves were generated using the Kaplan‐Meier method and visualized with the "survival" R package. The log‐rank test was used to compare two or more survival curves. A multivariate Cox regression model was applied to assess the effects of the ADC value, age, peritumoral edema, TERT promoter mutation status, and MGMT promoter status on the survival of adult primary GBM patients. This model was also applied to assess the impact of KPS, peritumoral edema, age, and Ki‐67 LI on the survival of primary GBM patients with an unmethylated MGMT promoter and TERT promoter mutations. Overall survival (OS) was defined as the time from the first operation to death or the date of the last follow‐up examination. Survival was last assessed in August 2017. The receiver operating characteristic (ROC) analysis was performed using the "pROC" R package and visualized with the "ggplot2″ R package. Unless stated otherwise, *P *≤* *0.05 was considered to indicate significance.

3. RESULTS {#cam41666-sec-0012}
==========

3.1. TERT/MGMT promoter status and Ki‐67 LI in adult primary GBM {#cam41666-sec-0013}
----------------------------------------------------------------

Three hundred four selected GBM samples (collected from patients aged at least 18 years) were assessed by Sanger sequencing to identify IDH1/2 mutations. Wild‐type IDH was present in 89.8% (273/304) of the total GBM samples. Among 273 GBM patients with wild‐type IDH, eight were previously diagnosed with low‐grade gliomas, accounting for 2.93% (8/273) of all GBM patients with wild‐type IDH. Two hundred sixty‐five wild‐type IDH GBM patients without antecedent history of low‐grade glioma were diagnosed as having primary GBMs (gross‐total resection rate: 72.6%, subtotal resection rate: 27.4%, 176 patients completed the above‐mentioned course of chemoradiation). TERT promoter mutations were observed in 66.42% (176/265) of all primary GBMs. Of these patients, 75% (132/176) had a C228T mutation, and 26.14% had a C250T mutation. Only two patients with primary GBMs had both C228T and C250T mutations, and most mutations were heterozygous. Pyrosequencing confirmed that the MGMT promoter was methylated in 38.49% (102/265) of the patients with primary GBMs. The mean Ki‐67 LI was 28% (range: 10%‐70%). Relationships between these three molecular biomarkers and other clinical demographic and MRI‐derived features are summarized in Table [1](#cam41666-tbl-0001){ref-type="table"}. A representative example of the main results is shown in Figure [S1](#cam41666-sup-0001){ref-type="supplementary-material"}.

3.2. Prediction and validation of survival‐related variables {#cam41666-sec-0014}
------------------------------------------------------------

A random survival forest analysis was performed to predict surrogate survival‐related variables, and five positive values were found to indicate the predictive power of the forest. The five key variables were MGMT promoter methylation status (MGMT), ADC value (ADC), age, tumor edema (edema), and TERT promoter mutation status (TERT) (Figure [2](#cam41666-fig-0002){ref-type="fig"}). The validation process indicates that the variables MGMT, ADC, age, and edema divided the primary GBM patients into two subgroups with significant differences in the predicted survival patterns (MGMT: *P *=* *0.00154, ADC: *P *=* *0.02874, age: *P *=* *0.00238, edema: *P *=* *0.03998) (Figure [3](#cam41666-fig-0003){ref-type="fig"}A‐D). TERT roughly divided the primary GBM patients into two different survival subgroups with a borderline‐adjusted significant *P* value (*P *=* *0.05791) (Figure [3](#cam41666-fig-0003){ref-type="fig"}E). A Cox PH regression model of the five variables was established, and the model exhibited a *P* value \<0.001 in all three tests (likelihood ratio test, Wald test, and log‐rank test), indicating the significance of the Cox PH regression model and soundly rejecting the omnibus null hypothesis. In the Cox PH regression model, the covariates age and MGMT remained statistically significant (*P *\<* *0.05) for OS, but the covariates ADC, edema, and TERT were not statistically significant (Table [2](#cam41666-tbl-0002){ref-type="table"}).

![Top Five Variables (MGMT, ADC, Age, Edema, and TERT) Identified as Surrogate Survival‐Related Variables Through Variable Importance (vimp) Measurements According to a Random Survival Forest Analysis](CAM4-7-3704-g002){#cam41666-fig-0002}

![Kaplan‐Meier curves for the Five Key Variables (A‐E) Identified in the Random Survival Forest Analysis: (A) MGMT, (B) ADC, (C) Age, (D) Edema, and (E) TERT](CAM4-7-3704-g003){#cam41666-fig-0003}

###### 

Cox PH regression model for OS

  Covariates   HR      95%CI          *z*‐score   *P*
  ------------ ------- -------------- ----------- ----------
  ADC          1.184   0.8851‐1.646   1.138       0.255281
  Age          1.710   1.2554‐2.329   3.403       0.000668
  Edema        1.334   0.9946‐1.788   1.924       0.054366
  TERT         1.287   0.9425‐1.758   1.587       0.112411
  MGMT         1.788   1.3182‐2.427   3.734       0.000188

HR, hazard ratio; CI, confidence interval; *P*,*P* value
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3.3. Subgroup analysis of the group with an unmethylated MGMT promoter and TERT promoter mutations {#cam41666-sec-0015}
--------------------------------------------------------------------------------------------------

Among the five important variables identified in the random survival forest analysis, the MGMT promoter methylation status and TERT promoter mutation status are key molecular tumor markers of GBM.[6](#cam41666-bib-0006){ref-type="ref"} We analyzed the relationship between the MGMT promoter methylation status and the survival benefit associated with the TERT promoter mutation status. The subgroup with both an unmethylated MGMT promoter and TERT promoter mutations represented 40% of all subgroups of different combinations of the MGMT promoter methylation status and TERT promoter mutation status (Table [1](#cam41666-tbl-0001){ref-type="table"}). A Kaplan‐Meier analysis showed that this subgroup demonstrated the worst OS among the subgroups (Figures [4](#cam41666-fig-0004){ref-type="fig"}A and [S2](#cam41666-sup-0001){ref-type="supplementary-material"}A). This subgroup was examined further through a LASSO regression analysis, and four candidate prognostic‐related variables (age, edema, Ki‐67, and KPS) with nonzero coefficients in the LASSO analysis were identified through a cross‐matching test (Figure [S2](#cam41666-sup-0001){ref-type="supplementary-material"}E‐G). The four covariates were introduced into the Cox PH regression model. Age and edema were identified as independent prognostic factors (Figure [S2](#cam41666-sup-0001){ref-type="supplementary-material"}H). The heatmap shows the distribution of factors related to adult primary GBM in the subgroup with an unmethylated MGMT promoter and TERT promoter mutations and in the other subgroups (Figure [4](#cam41666-fig-0004){ref-type="fig"}B).

![A, Analysis of the Survival of Patients with Different MGMT Promoter Methylation Statuses and TERT Promoter Mutation Statuses in the Research Cohort. B, Heatmap showing the distribution of adult primary GBM‐related factors in the subgroup with an unmethylated MGMT promoter and TERT promoter mutations (group A) and the other subgroups](CAM4-7-3704-g004){#cam41666-fig-0004}

3.4. Analysis of multiple primary GBM‐related factors {#cam41666-sec-0016}
-----------------------------------------------------

A multivariate survival analysis of the prognostic effect of the interaction among the five important variables identified in the random survival forest analysis (MGMT, TERT, age, edema, and ADC) was performed. A subgroup with obvious edema and TERT promoter mutations had an increasingly negative prognosis compared with the other subgroups with different edema and TERT promoter status combinations (Figures [5](#cam41666-fig-0005){ref-type="fig"}A and [S2](#cam41666-sup-0001){ref-type="supplementary-material"}B). The subgroup combining younger age with a wild‐type TERT promoter exhibited enhanced OS compared with the other subgroups with different age and TERT promoter mutation status combinations (Figures [5](#cam41666-fig-0005){ref-type="fig"}B and [S2](#cam41666-sup-0001){ref-type="supplementary-material"}C). The subgroup combining older age with an unmethylated MGMT promoter had poorer OS than the other subgroups with different age and MGMT promoter methylation status combinations (Figures [5](#cam41666-fig-0005){ref-type="fig"}C and [S2](#cam41666-sup-0001){ref-type="supplementary-material"}D). We performed an ROC analysis to compare the sensitivities and specificities of the predictive ability of the TERT mutation status and the MGMT promoter methylation status among the other factors related to adult primary GBM listed in Table [1](#cam41666-tbl-0001){ref-type="table"}. The areas under the ROCs (AUCs) for these factors were determined and compared. As shown in Figure [5](#cam41666-fig-0005){ref-type="fig"}D, necrosis had the highest AUC value (0.5823) for predicting the TERT promoter mutation status. The AUC for necrosis was significantly different than those for KPS (AUC: 0.4886, *P *=* *0.03555), T1/Flair ratio (AUC: 0.4273, *P *=* *0.001013), CET (AUC: 0.5454, *P *=* *0.04617), gender (AUC: 0.514, *P *=* *0.04414), MGMT (AUC: 0.4809, *P *=* *0.019), and nCET (AUC: 0.4725, *P *=* *0.00712). As shown in Figure [5](#cam41666-fig-0005){ref-type="fig"}E, Ki‐67 had the highest AUC value (0.5616) for predicting the MGMT promoter methylation status. The AUC obtained for Ki‐67 was different from those for KPS (AUC: 0.5389, P = 0.02882), edema (AUC: 0.5586, *P *=* *0.009726), T1/Flair ratio (AUC: 0.5255, *P *=* *0.03345), necrosis (AUC: 0.5433, *P *=* *0.0218), cysts (AUC: 0.5482, *P *=* *0.01808), and nCET (AUC: 0.547, *P *=* *0.009551).

![Kaplan‐Meier Curves Comparing Patients with Tumors with a TERT Promoter Mutation and Patients with Tumors with a Wild‐type TERT Promoter. The patients were stratified by the peritumoral edema level (A). Tumors bearing a TERT promoter mutation compared with wild‐type tumors (B) and tumors with a methylated MGMT promoter vs an unmethylated MGMT promoter (C). The tumors in (B) and (C) were stratified by age. ROC curves for TERT (D) and MGMT (E) promoter status among the adult primary GBM‐related factors](CAM4-7-3704-g005){#cam41666-fig-0005}

In addition, the TERT promoter mutation status was positively associated with the T1/Flair ratio (*P* = 0.0224) and necrosis (*P* = 0.01). The Ki‐67 LI was negatively associated with the ADC value (*P* = 0.01174) and cysts (*P* = 0.0223). No primary GBM‐related factors were associated with the MGMT promoter methylation status (Table [1](#cam41666-tbl-0001){ref-type="table"}).

4. DISCUSSION {#cam41666-sec-0017}
=============

Through a random survival forest analysis, we observed the following five key variables: MGMT promoter methylation status, TERT promoter mutation status, age, peritumoral edema and ADC value. The validation of their prognostic function by Kaplan‐Meier and Cox PH regression analyses revealed that age and the MGMT promoter methylation status were important prognostic markers that provide independent information. Primary GBM comprises 84.21% (265/304) of all adult GBM patients, and this ratio is lower than that reported in previous studies.[1](#cam41666-bib-0001){ref-type="ref"}, [6](#cam41666-bib-0006){ref-type="ref"} This discrepancy might be due to the classification of primary and secondary GBM based on the clinical history or IDH1/2 status in previous studies. However, we define primary GBM based on a combination of these two methods, and as a result, we ensured that the patients selected in our study are primary GBM patients and avoided the inclusion of secondary GBM patients, which could strongly interfere with the results. We did not find that the TERT promoter mutation status is an independent prognostic biomarker of primary GBM, even though the TERT mutation status analyses revealed borderline significance in the univariate survival analysis (Figure [3](#cam41666-fig-0003){ref-type="fig"}E). However, some GBM studies that included both primary and secondary GBM patients suggested that TERT promoter mutations are independently associated with a negative prognosis.[19](#cam41666-bib-0019){ref-type="ref"}, [20](#cam41666-bib-0020){ref-type="ref"} We speculate that the prognostic value of TERT promoter mutations in relation to poor survival is partly due to the IDH status. TERT promoter mutations without IDH mutations cannot reflect the different survival statuses of GBM patients.

Our results show that poor survival associated with TERT mutations was only observed in patients exhibiting high peritumoral edema, and increased survival associated with a wild‐type TERT promoter was only observed in young patients. We predicted that patients with high peritumoral edema that was preoperatively detected through MRI imaging and TERT promoter mutations that were postoperatively detected in tumor tissue would have a poorer prognosis and a higher mortality. These patients would likely need a more aggressive treatment strategy than young patients with a wild‐type TERT promoter, who may achieve a favorable oncologic outcome if treated. Another striking result of our study is that poor survival associated with an unmethylated MGMT promoter is detected only in aged patients who have undergone chemoradiotherapy after maximal safe resection of the tumor.

We also identified a primary GBM molecular subgroup of adult patients that showed promise for providing prognostic indications and differentiating treatment opinions. The subgroup with an unmethylated MGMT promoter and TERT promoter mutations exhibited worse survival than the other subgroups with different TERT promoter mutation status and MGMT promoter methylation status combinations (Figure [4](#cam41666-fig-0004){ref-type="fig"}A). TERT mutations might portend a more deleterious primary GBM if the MGMT promoter is unmethylated. Through a LASSO analysis, we discovered that the main factors that affected survival in this group were age and Ki‐67 positivity. The heatmap (Figure [4](#cam41666-fig-0004){ref-type="fig"}B) revealed that patients with low ADC values, obvious edema, a high Ki‐67 LI, obvious necrosis, unobvious nCET, deep white matter invasion, and obvious CET were enriched in this group. Some of these factors might represent MRI imaging markers for the subgroup of primary GBM patients with an unmethylated MGMT promoter and TERT promoter mutations that can be easily and noninvasively acquired. The exact mechanism that describes these results needs to be further explored and validated in future studies. We demonstrated that the Ki‐67 LI is negatively associated with the ADC value through Pearson\'s chi‐squared test (Table [1](#cam41666-tbl-0001){ref-type="table"}). A univariate survival analysis showed that a lower ADC value is associated with poorer survival in adult primary GBM patients (Figure [3](#cam41666-fig-0003){ref-type="fig"}B). Therefore, based on the heterogeneity of primary GBM, measuring the ADC value might help identify the most appropriate biopsy site.

The ROC analysis showed that Ki‐67 demonstrated the highest AUC value among primary GBM‐related factors for assessing the MGMT promoter methylation status. However, Pearson\'s chi‐squared test showed no statistical relationship between the Ki‐67 LI and MGMT promoter methylation status. No MRI‐derived features or clinical factors were found to predict the MGMT promoter methylation status. We speculate that the MGMT promoter methylation status might contribute to prognosis through mechanisms that differ from those of other primary GBM‐related factors and thus provides unique prognostic information for adult primary GBM. The ROC analysis demonstrated that necrosis had the highest AUC value for assessing the TERT promoter mutation status, and Pearson\'s chi‐squared test showed that necrosis was positively associated with the TERT promoter mutation status. Our study showed that TERT promoter mutations (66.42%) occur in many primary GBMs, and the frequency at which these were detected was in line with previous studies (58%‐75%).[21](#cam41666-bib-0021){ref-type="ref"}, [22](#cam41666-bib-0022){ref-type="ref"} TERT promoter mutations are frequency associated with malignant tumor progression and a capacity for enhanced cell proliferation.[23](#cam41666-bib-0023){ref-type="ref"} The unenhanced region on MRI, which represents pathological necrosis, reflects tumor progression. Tumor necrosis is caused by chronic ischemic injury due to rapid tumor proliferation.[24](#cam41666-bib-0024){ref-type="ref"} Our study confirms that the TERT promoter mutation status is correlated with pathological necrosis and that necrosis detected through MRI reflects the TERT promoter mutation status.

This study has several limitations. Our analysis was limited by its retrospective nature, and our findings were obtained from a single center. The results should be confirmed in a prospective, multicenter study. The sequencing method used in this study was not high‐throughput and could only report confirmed hotspot mutation sites. We cannot rule out the possibility of new mutation sites in the IDH and TERT promoters. Measurement of the ADC value can be affected by several technical factors, such as the timing of contrast agent administration, the coregistration of different images, and the selection of the region of interest (ROI) on the ADC map. The establishment of a uniform standard is necessary for the measurement of more accurate ADC values. Despite our attempts to minimize differences among treatments by only selecting patients who received standard surgery and concurrent chemoradiation therapy, as described in the CGCG clinical practice guidelines,[7](#cam41666-bib-0007){ref-type="ref"} the patients could have been exposed to a variety of other chemotherapies throughout their treatment. In addition, the surgeons were responsible for ensuring that the patients had undergone maximal safe resection, which can lead to selection bias and thereby affect the analysis of the results.

In summary, methylation of the MGMT promoter (38.49%) and mutations in the TERT promoter (66.42%) are prognostically important molecular events in adult primary GBM. The MGMT promoter methylation status and TERT promoter mutation status, combined with MRI‐derived and clinical features, can define different subgroups with distinct responses to the current treatment options. The combination of these factors results in a stronger survival prediction for adult patients with primary GBM. No imaging‐related features can predict the MGMT promoter methylation status. MRI‐detected necrosis is positively associated with the TERT promoter mutation status. If confirmed in prospective studies, these findings might have clinical implications in identifying critical factors for improving patient outcomes and treatment selection.
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